What smart money is saying about Embecta
EMBC
No fund has written a full thesis on Embecta in our archive, but 1 fund letter reports a position in it — most recently Buffalo funds High Yield Fund in June 2026.
Get an email when a fund writes about it
1
Reported positions
0
Bought
1
Sold
1
Letter
Position history
Every position in Embecta on record in the archive was reported in Q2 2026, across 1 fund letter — 1 trimmed or exited.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q2 2026 | 1 | 0 | 1 | 0 |
Fund activity · 1 position · 1 move
- June 2026
“TOP DETRACTORS The Embecta term loan and 6.75% ‘30 corporate bonds, along with Dye & Durham 8.25% ’29 corporate bonds were the worst performing issues in the portfolio for the quarter. Embecta reported poor earnings and cut full-year guidance on weaker than expected demand for its diabetes pen needles. Dye & Durham bonds sold off after reporting weaker than expected earnings and several top executives were removed. The fund no longer holds the Embecta or Dye & Durham corporate bonds.”
Embecta
Read the letters behind these Embecta positions
Every quote above comes from a fund letter in our archive. Get unlimited access to the letters themselves — and to Warren AI, which reads all of them for you.
View plans→Share this ledger